莱沃西门丹:对患有功能不全的患者的一种新疗法策略
Xinwen Liu1, Mengkai Lu1, Yanna Yu1
1Department of Pharmacy, the Affiliated Hospital of Shaoxing University, Shaoxing, 312000, PR China.
Cardiovascular drugs and therapy
|August 7, 2024
概括
一种心力衰竭药物Levosimendan通过抗亡,抗炎和抗氧化作用对功能产生保护作用. 它在严重功能衰竭和心脏手术后的使用仍在研究中.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 莱沃西门丹是一种敏感剂,用于急性不补偿性心力衰竭.
- 它显示出潜在的脏保护机制,包括抗亡,抗炎和抗氧化作用.
- 它在心力衰竭和功能不全患者或心脏手术后患者中的作用需要进一步探索.
研究的目的:
- 研究levosimendan在患有严重功能不全的患者中的应用和影响.
- 提供levosimendan对功能影响的全面概述,特别是在心脏手术后.
主要方法:
- 文献综述侧重于涉及左侧肌肉和功能的研究.
- 分析levosimendan.com提供的脏保护的体内机制.
- 检查关于levosimendan在严重功能障碍和心脏手术后环境中使用的临床数据.
主要成果:
- 莱沃西门丹在体内表现出多方面的脏保护性质.
- 有证据表明,对患有功能不全的心力衰竭患者的功能有潜在的益处.
- 药物在严重功能障碍和心脏手术后的疗效和安全性仍然是正在进行的临床辩论和研究的主题.
结论:
- 莱沃西门丹具有固有的保护性质.
- 进一步的研究至关重要,以澄清其在严重功能衰竭和心脏手术后情境中的作用和安全性.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
406
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
406
Heart Failure Drugs: Diuretics
353
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
353
Heart Failure Drugs: Inotropic Agents
548
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
548
Renal Failure: Dose Adjustments
77
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
77
Antihypertensive Drugs: Potassium-Sparing Diuretics
488
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
488
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K


